CMV-GFP AAV (Serotype MyoAAV 2A)

CMV-GFP AAV (Serotype MyoAAV 2A) is an advanced viral vector designed for highly efficient gene delivery, particularly suited for muscle cells. One of the key features of this system is its ability to utilize an adeno-associated virus (AAV) serotype specifically engineered for muscle tissue targeting. This targeted delivery ensures high transduction efficiency and minimal off-target effects, making it a preferred choice for applications requiring precise gene expression in skeletal muscle. The cytomegalovirus (CMV) promoter drives the expression of the green fluorescent protein (GFP) reporter gene, providing a strong and stable expression profile. This feature allows for the visualization of transduction efficiency and gene expression through fluorescence microscopy, which is crucial for monitoring the effectiveness of gene therapy or other experimental applications. Furthermore, the MyoAAV 2A system utilizes 2A peptide technology, enabling the co-expression of multiple proteins, thus allowing for the synthesis of different polypeptides from a single transcript and enhancing the versatility of this vector system.

In gene therapy, this vector has been used to study and potentially correct genetic disorders affecting muscle function, such as muscular dystrophy. By delivering therapeutic genes directly to muscle cells, researchers aim to restore normal gene function, promote muscle regeneration, and improve overall muscle health. The ability to visualize GFP expression allows researchers to track the success of gene delivery and its subsequent effects on muscle cells in living organisms. Beyond therapeutic applications, this vector plays a significant role in basic research, contributing to the study of muscle biology, gene regulation, and cellular responses to various stimuli. Researchers can use CMV-GFP AAV to explore the dynamics of protein interactions and the mechanisms involved in muscle cell differentiation and hypertrophy.